CN1288383A - 贯叶金丝桃和甲基供体组合物及其用途 - Google Patents
贯叶金丝桃和甲基供体组合物及其用途 Download PDFInfo
- Publication number
- CN1288383A CN1288383A CN99802145A CN99802145A CN1288383A CN 1288383 A CN1288383 A CN 1288383A CN 99802145 A CN99802145 A CN 99802145A CN 99802145 A CN99802145 A CN 99802145A CN 1288383 A CN1288383 A CN 1288383A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- compositions
- methyl donor
- treatment
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明提供了用于情绪提高,调节并治疗抑郁症及焦虑症,和哺乳动物的经前综合症相关症状的缓解的治疗组合物和方法。该组合物含有贯叶金丝桃(Hypericum perforatum)和一种甲基供体,例如S-腺苷甲硫氨酸。
Description
本申请根据35U.S.C.§119要求美国的临时申请登记号No.60/071,287的优先权的利益,其内容因此也通过引用被合并到本申请中。
发明的背景
1.发明的领域
本发明涉及用于情绪的提高和调节和抑郁症和焦虑症的治疗以及哺乳动物经前综合症(“PMS”)相关症状的缓解的治疗组合物。
2.相关技术的描述
贯叶金丝桃(Hypericum perforatum)是一种含有金丝桃素,类黄酮,酚类,丹宁酸及挥发性油类的草本植物。贯叶金丝桃的甲醇提取物在临床上对于情绪的提高和抑郁症的治疗是有效的,且其全草、提取物及其衍生物被广泛地用于抗抑郁、神经紧张以及睡眠失调。
鼠突触小体的研究表明提取物可能的作用是突触后受体对5-羟色胺摄取的抑制作用产生的。因此人们确信贯叶金丝桃和/或其提取物及其衍生物通过5-羟色胺能系统中的活性而发挥抗抑郁和心情调节作用。
S-腺苷甲硫氨酸(SAMe)是一种天然存在的分子,其可以在所有的活体生物包括酵母、植物与所有的动物品种中找到。SAMe在体内由甲硫氨酸和三磷酸腺苷(ATP)在ATP-甲硫氨酸S-腺苷转移酶催化的反应中合成。SAMe实际上广泛分布在所有的身体组织中作为涉及酶的甲基转移作用(通过该过程一个甲基被转移到不同的受体中)的许多生物反应的底物。
在过去的二十年中,大量的研究表明了大脑中甲基化作用的重要性。特别地,人们已经确定中枢神经系统(CNS)的正常机能需要足够的甲基供体SAMe的供给。甲基化障碍,叶酸盐与一元胺前体的不足,以及肾上腺素能系统,多巴胺能系统以及5-羟色胺能系统的破坏都与抑郁症的病因有关。神经递质的合成涉及SAMe的甲基基团转移。抑郁症病人被确认其SAMe的水平有所降低。同时,研究表明SAMe刺激多巴胺能系统并显示出作为一种抗抑郁药物是有效的,大概是通过其肾上腺素能及多巴胺能相关活性而起作用。
发明的概述
本发明提供了用于情绪的提高调节和抑郁症和焦虑症的治疗以及哺乳动物经前综合症相关症状的缓解的治疗组合物和方法。上述组合物含有贯叶金丝桃(Hypericum pertoratum)以及一种例如S-腺苷甲硫氨酸的甲基供体。
本发明进一步的主要目的是提供这样一种治疗组合物,其是nutraceutical,即只包括能提供有效的治疗作用的成分的组合物。
由于它们的作用方式不同,甲基供体如SAMe及贯叶金丝桃(和/或其任何活性成分或提取物)的组合被确认对于情绪的提高、调节、抑郁症和焦虑症的治疗以及经前综合症相关症状的缓解产生一种协同的效果。所述的组合通过令人吃惊的其作用机理上的互补而出乎意料地提高了每一种单个成分的作用,其中5-羟色胺能和非5-羟色胺能神经递质系统被同时且协同地受到影响。
用贯叶金丝桃和/或其任何活性成分或提取物的治疗需要3-4周来观察作为一种情绪提高剂和抗抑郁剂的临床效果。在给药1-2周后,甲基供体例如SAMe对情绪提高/抗抑郁可以是有效的。另一个出乎意料的优点是所述组合物在短期给药后产生了效果,从而显著地缩短了单独用贯叶金丝桃或甲基供体给药产生治疗效果所需的给药期。
这种组合物提供了贯叶金丝桃对5-羟色胺能功能的较高活性,以及甲基供体如SAMe介导的在神经递质合成中的甲基化反应的二者的协同效果。
可选择的成分也可以被加到本发明的治疗组合物中。这样的添加剂包括但不限于叶酸,维生素B6,维生素B12,维生素C,以及生物蝶呤,因为这些营养物的缺乏也会导致抑郁症和焦虑症。组合物中任选的增强草药药性的添加剂包括但不限于甘草,姜,迷迭香,人参(全部物种)的全草或者其任何活性成分或提取物,因为这些植物材料的化学成分提供人类抗抑郁的效果。
优选实施方案的描述
任何与所有的由一种甲基供体以及贯叶金丝桃和/或其任何活性成分或提取物组成的治疗组合物都在本发明的范围内。所述的组合物选择性地包括其他的治疗成分例如叶酸,维生素B6,维生素B12,维生素C。
一方面,本发明提供一种用于情绪提高和调节和用于抑郁症和焦虑症的治疗以及人类经前综合症相关症状的缓解的治疗组合物,其包括与甲基供体相混合的治疗协同量的全草贯叶金丝桃,其任何活性成分或提取物。
出于此种考虑,甲基供体对于本发明获得有益的效果是必要的,相关的但是不含有甲基的成分,例如前体或不含有甲基的衍生物与本发明无关。
甲基供体优选为S-腺苷甲硫氨酸。然而,其它的甲基供体也可以被利用,如5-甲基-四氢叶酸,胆碱,甲硫氨酸,甜菜碱和甲基-维生素B12。
贯叶金丝桃的剂量优选为25-10,000mg,以全草,任何其活性成分或提取物的形式。
甲基供体的剂量优选为10-5000mg。
本发明的治疗组合物可以包括另外的成分,包括但不限于叶酸50-1000mcg,维生素B6 10-2000mg,维生素B12 10-3000mcg,以及生物蝶呤,其前体或衍生物25-2000mg,维生素C 30-500mg;以及甘草,姜,迷迭香,人参(全部物种)的全草,其提取物或衍生物。
另一方面,本发明提供一种用于情绪提高和调节和用于抑郁症和焦虑症的治疗以及人类经前综合症相关症状的缓解的治疗组合物,其包括与甲基供体相混合的治疗协同量的全草贯叶金丝桃,或者其任何活性成分或提取物,所述甲基供体例如是S-腺苷甲硫氨酸,其中以全草或任何其活性成分或提取物形式的贯叶金丝桃的剂量为25-10,000mg。
在优选方面,本发明提供一种用于情绪提高和调节和用于抑郁症和焦虑症的治疗以及人经前综合症相关症状的缓解的治疗组合物,其包括与甲基供体相混合的在5-羟色胺能系统中有活性的治疗协同量的贯叶金丝桃,所述甲基供体用于需要情绪提高和调节和抑郁症和焦虑症的治疗以及经前综合症相关症状的缓解的人体中神经递质合成反应中的甲基化过程。
本发明也提供了一种用于影响情绪提高和调节和用于抑郁症和焦虑症的治疗以及人类经前综合症相关症状的缓解的方法,包括给药治疗有效量的治疗协同组合物的步骤,所述组合物含有与甲基供体相混合的全草贯叶金丝桃,或者其任何活性组分或其提取物。甲基供体优选为S-腺苷甲硫氨酸。
根据本发明,治疗组合物可通过任何有效的途径给药,但优选为口服或非肠道给药。
在一方面,本发明的方法使用一种治疗组合物其进一步包括一种含有一种或多种下述营养物的混合物:叶酸50-1000mcg,维生素B610-2000mg,维生素B12 10-3000mcg,以及生物蝶呤,其前体或衍生物25-2000mg,维生素C 30-500mg;以及甘草,姜,迷迭香,人参(全部物种)的全草,其提取物或衍生物。
尽管本发明的优选实施方案已于上面描述,但是必须意识到本发明的很多修改和改变根据上述教导是可能的并且在下述权利要求范围内并未离开本发明的精神和设定的范围。
Claims (15)
1.一种用于情绪提高和调节和用于抑郁症和焦虑症的治疗以及人类经前综合症相关症状的缓解的治疗组合物,所述组合物含有与甲基供体相混合的治疗有效量的贯叶金丝桃。
2.如权利要求1所述的组合物,其中的贯叶金丝桃为全草或其任何活性组分或其提取物的形式。
3.如权利要求1所述的组合物,其中的甲基供体包括S-腺苷甲硫氨酸。
4.如权利要求1所述的组合物,其中为全草,或其任何活性组分或其提取物的形式的贯叶金丝桃的量为大约25至大约10,000mg。
5.如权利要求1所述的组合物,其中的甲基供体的量为大约10至大约5000mg。
6.如权利要求1所述的组合物,其进一步含有叶酸,维生素B6,维生素B12,生物蝶呤,维生素C或甘草,姜,迷迭香,人参的全草,其提取物或衍生物中的至少一种。
7.如权利要求6所述的组合物,其进一步含有叶酸50-1000mcg,维生素B6 10-2000mg,维生素B12 10-3000mcg,生物蝶呤25-2000mg,维生素C30-500mg中的至少一种。
8.一种用于情绪提高和调节和用于抑郁症和焦虑症的治疗以及人类经前综合症相关症状的缓解的治疗组合物,其包括:与甲基供体相混合的在5-羟色胺能系统中有活性的治疗协同量的贯叶金丝桃,所述甲基供体用于需要情绪提高和调节和抑郁症和焦虑症的治疗以及经前综合症相关症状的缓解的人体中神经递质合成反应中的甲基化过程。
9一种用于影响情绪提高和调节和用于抑郁症和焦虑症的治疗以及人类经前综合症相关症状的缓解的方法,其包括:对需要治疗的患者给药治疗有效量的组合物的步骤,所述组合物包括与甲基供体相组合的贯叶金丝桃。
10.如权利要求9所述的方法,其中的贯叶金丝桃为全草或其任何活性组分或提取物的形式。
11.如权利要求9所述的方法,其中的甲基供体包括S-腺苷甲硫氨酸。
12.如权利要求9所述的方法,其中的组合物口服给药。
13.如权利要求9所述的方法,其中的组合物是非肠道给药。
14.如权利要求9所述的方法,其中的组合物进一步含有包括叶酸,维生素B6,维生素B12,生物蝶呤,维生素C或甘草,姜,迷迭香或人参的全草,其提取物或衍生物中的至少一种的混合物。
15.如权利要求14所述的方法,其中的组合物进一步包括叶酸50-1000mcg,维生素B6 10-2000mg,维生素B12 10-3000mcg,以及生物蝶呤25-2000mg,维生素C 30-500mg中的至少一种。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7128798P | 1998-01-13 | 1998-01-13 | |
US60/071,287 | 1998-01-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1288383A true CN1288383A (zh) | 2001-03-21 |
Family
ID=22100397
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN99802145A Pending CN1288383A (zh) | 1998-01-13 | 1999-01-13 | 贯叶金丝桃和甲基供体组合物及其用途 |
Country Status (7)
Country | Link |
---|---|
US (1) | US6096317A (zh) |
EP (1) | EP1047440A1 (zh) |
JP (1) | JP2002509111A (zh) |
CN (1) | CN1288383A (zh) |
AU (1) | AU746072B2 (zh) |
CA (1) | CA2317671A1 (zh) |
WO (1) | WO1999036080A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2110135A3 (en) * | 2005-03-25 | 2010-12-22 | Beijing Wonner Biotech Ltd. Co. | A pharmaceutical composition for treating depression and method for preparation thereof |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1301679B1 (it) * | 1998-06-10 | 2000-07-07 | Indena Spa | Derivati dell'iperforina, loro uso e formulazioni che licontengono. |
JP2002527484A (ja) * | 1998-10-19 | 2002-08-27 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | セントジョーンズワートならびにジヒドロおよびテトラヒドロ葉酸の誘導体を含有する、うつ病の治療および予防のための天然製剤 |
US8642581B1 (en) | 2000-02-11 | 2014-02-04 | Brian D. Halevie-Goldman | Compositions and methods for the production of S-adenosylmethionine within the body |
US7208180B2 (en) * | 2000-05-08 | 2007-04-24 | N.V. Nutricia | Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith |
US7226916B1 (en) | 2000-05-08 | 2007-06-05 | N.V. Nutricia | Preparation for the prevention and/or treatment of vascular disorders |
AU2001275146A1 (en) * | 2000-06-01 | 2001-12-11 | Theralife, Inc. | Compositions for enhancing therapeutic effects containing herbals and/or nutritional supplements and/or minerals and/or vitamins |
US20040234544A1 (en) * | 2001-08-09 | 2004-11-25 | Ralf Jager | Formulation containing (lyso-)phosphatidylserine for the prevention and treatment of stress states in warm blooded animals |
US7674482B2 (en) * | 2002-08-27 | 2010-03-09 | Targeted Medical Pharma Inc. | Method and compositions for potentiating pharmaceuticals with amino acid based medical foods |
JP2004262922A (ja) * | 2003-02-13 | 2004-09-24 | Ezaki Glico Co Ltd | サイクルサプリメント |
GB0313630D0 (en) * | 2003-06-12 | 2003-07-16 | Wwk Trust The | Compositions for the enhanced treatment of depression |
US8075910B2 (en) * | 2004-05-20 | 2011-12-13 | Pbm Pharmaceuticals, Inc. | Oral compositions comprising edible oils and vitamins and/or minerals and methods for making oral compositions |
US20060115556A1 (en) * | 2004-12-01 | 2006-06-01 | Foulger Sidney W | Nutritional supplement drink containing xanthone extracts |
US20060115555A1 (en) * | 2004-12-01 | 2006-06-01 | Foulger Sidney W | Nutritional supplements containing xanthone extracts |
EP1930019A1 (en) * | 2006-11-24 | 2008-06-11 | DSMIP Assets B.V. | Rosemary extracts, dietary and pharmaceutical compositions containing them and their uses |
EP1925313A1 (en) * | 2006-11-24 | 2008-05-28 | Nestec S.A. | Prevention and treatment of disorders connected to impaired neurotransmission |
WO2010027014A1 (ja) * | 2008-09-04 | 2010-03-11 | 株式会社カネカ | S-アデノシル-l-メチオニンの吸収性を高める方法およびs-アデノシル-l-メチオニンの吸収性が高められた組成物 |
WO2012002986A2 (en) * | 2009-12-21 | 2012-01-05 | The Regents Of The University Of California | Decellularized and delipidized extracellular matrix and methods of use |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4435424A (en) * | 1980-07-15 | 1984-03-06 | Massachusetts Institute Of Technology | Process for improving vigor and mood in normal human patients |
LU85643A1 (fr) * | 1984-11-16 | 1986-06-04 | Oreal | Composition cosmetique thermo-amincissante a base d'extraits vegetaux oleosolubles |
IL79661A (en) * | 1986-08-08 | 1991-01-31 | Yeda Res & Dev | Antiviral composition containing hypericin or pseudohypericin |
US4973467A (en) * | 1989-10-13 | 1990-11-27 | Natrol, Inc. | Dietary supplement for adults |
US5514714A (en) * | 1990-08-23 | 1996-05-07 | New York University | Methods and polycyclic aromatic compound containing compositions for treating T-cell-mediated diseases |
US5453428A (en) * | 1991-02-14 | 1995-09-26 | The Mount Sinai School Of Medicine Of The City Of New York | Method and composition for the treatment of apathy-amotivation syndrome |
AP387A (en) * | 1991-09-13 | 1995-07-31 | Siegbert Heinrich Bissbort | Therapeutical uses of L-methionine and compositions thereof. |
US5273754A (en) * | 1992-03-27 | 1993-12-28 | Mann Morris A | Appetite suppressant composition and method relating thereto |
US5470846A (en) * | 1994-01-14 | 1995-11-28 | Sandyk; Reuven | Treatment of neurological and mental disorders |
US5834443A (en) * | 1996-05-21 | 1998-11-10 | Masiello; Domenick J. | Composition and method for treating herpes simplex |
US5798101A (en) * | 1997-01-22 | 1998-08-25 | Hpf, L.L.C. | Herbal appetite suppressant and weight loss composition |
US5820867A (en) * | 1997-04-24 | 1998-10-13 | Bewicke; Calverly M. | General anti-depressant composition for dietary supplement |
-
1999
- 1999-01-13 CA CA002317671A patent/CA2317671A1/en not_active Abandoned
- 1999-01-13 AU AU22278/99A patent/AU746072B2/en not_active Ceased
- 1999-01-13 JP JP2000539853A patent/JP2002509111A/ja active Pending
- 1999-01-13 EP EP99902254A patent/EP1047440A1/en not_active Withdrawn
- 1999-01-13 CN CN99802145A patent/CN1288383A/zh active Pending
- 1999-01-13 US US09/229,445 patent/US6096317A/en not_active Expired - Fee Related
- 1999-01-13 WO PCT/US1999/000816 patent/WO1999036080A1/en not_active Application Discontinuation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2110135A3 (en) * | 2005-03-25 | 2010-12-22 | Beijing Wonner Biotech Ltd. Co. | A pharmaceutical composition for treating depression and method for preparation thereof |
Also Published As
Publication number | Publication date |
---|---|
WO1999036080A1 (en) | 1999-07-22 |
AU2227899A (en) | 1999-08-02 |
AU746072B2 (en) | 2002-04-11 |
JP2002509111A (ja) | 2002-03-26 |
EP1047440A1 (en) | 2000-11-02 |
US6096317A (en) | 2000-08-01 |
CA2317671A1 (en) | 1999-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1288383A (zh) | 贯叶金丝桃和甲基供体组合物及其用途 | |
KR101952416B1 (ko) | 관절 건강을 위한 조성물 및 방법 | |
KR101627065B1 (ko) | 항 인플루엔자 바이러스제 | |
US20010033872A1 (en) | Combinations of tyrosine, methylating agents, phospholipids, fatty acids, and St. John's Wort for the treatment of mental disturbances | |
Muazu et al. | A review of traditional plants used in the treatment of epilepsy amongst the Hausa/Fulani tribes of northern Nigeria | |
Yarnell et al. | Clinical botanical medicine | |
Osuchowski et al. | Alterations in regional brain neurotransmitters by silymarin, a natural antioxidant flavonoid mixture, in BALB/c mice | |
CN101732461B (zh) | 用于改善脑功能和/或治疗脑病的组合物 | |
Wagner | Natural products chemistry and phytomedicine in the 21st century: new developments and challenges | |
Rathee et al. | Natural memory boosters | |
Hosseini et al. | The therapeutic effects of medicinal plants on depression and anxiety disorders | |
Farzan et al. | Phytotherapy for seizure: An overview of the most important indigenous Iranian medicinal plants with anticonvulsant properties | |
Peddapalli et al. | Therapeutic potential of Piper betle: an amazing nature’s medicinal reservoir | |
EP1502597B1 (en) | Compositions for the treatment of anxiety and associated disorders | |
Wagner | Natural products chemistry and phytomedicine research in the new millennium: new developments and challenges | |
CA2348693C (en) | Natural formulation for the treatment and prevention of depression, containing st john's wort and derivatives of dihydro- and tetrahydrofolic acid | |
CN113209170A (zh) | 一种缓解口腔溃疡的电子雾化液 | |
Qureshi et al. | Preclinical safety, anxiolytic and antidepressant activity of Sufoof Jawahar Mohra: A Unani formulation | |
Sayuti et al. | Effect of Caesalpinia Sappan Extract on the preventive of relapse after orthodontic treatment | |
Al-Ali et al. | Effect of the alcoholic or the aqueous extracts of Ziziphus spina-christi leaves on the white blood cells and the oxidative stress status in local rabbits | |
Yaşar et al. | Systemic Investigation of Acute Toxicity of Some Food Supplements on the Market in Turkey | |
BG66011B1 (bg) | Състав от растителен произход | |
de Morais Pinheiro et al. | Plant-based Bone Grafting: The Future of Bone Healing | |
Arulsamy et al. | Neuroactive drugs–A perspective on drugs of synthetic and medicinal plants origin | |
Agung et al. | Nutrition Bali Holy Medicinal Plants For General and Orodental Health |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |